Dr. Halmos on Immunotherapy in Squamous NSCLC

Balazs Halmos, MD, MS
Published: Thursday, Oct 18, 2018



Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

Within the last year, physicians have seen frontline data from the IMpower131 and KEYNOTE-407 trials. IMpower131 looked at the combination of taxane-based doublet chemotherapy plus atezolizumab (Tecentriq). Though the study had shown significant progression-free survival (PFS) benefit, it failed to translate into an overall survival (OS) benefit, says Halmos.

The KEYNOTE-407 study looked at the combination of carboplatin/paclitaxel or nab-paclitaxel (Abraxane), plus or minus pembrolizumab (Keytruda). This was followed by maintenance pembrolizumab versus placebo. The addition of pembrolizumab showed a PFS benefit as well as a substantial OS benefit, irrespective of PD-L1 expression, adds Halmos. This translated to an approximately 20% improvement in response rates, changing the frontline standard, concludes Halmos.
SELECTED
LANGUAGE


Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

Within the last year, physicians have seen frontline data from the IMpower131 and KEYNOTE-407 trials. IMpower131 looked at the combination of taxane-based doublet chemotherapy plus atezolizumab (Tecentriq). Though the study had shown significant progression-free survival (PFS) benefit, it failed to translate into an overall survival (OS) benefit, says Halmos.

The KEYNOTE-407 study looked at the combination of carboplatin/paclitaxel or nab-paclitaxel (Abraxane), plus or minus pembrolizumab (Keytruda). This was followed by maintenance pembrolizumab versus placebo. The addition of pembrolizumab showed a PFS benefit as well as a substantial OS benefit, irrespective of PD-L1 expression, adds Halmos. This translated to an approximately 20% improvement in response rates, changing the frontline standard, concludes Halmos.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x